Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $240,525.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $32.07, for a total transaction of $240,525.00. Following the completion of the transaction, the insider directly owned 32,316 shares of the company’s stock, valued at approximately $1,036,374.12. The trade was a 18.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Tuesday, September 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.06, for a total transaction of $202,950.00.
• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $84,350.43.
• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00.

Maze Therapeutics Trading Down 1.4%

MAZE stock traded down $0.45 during midday trading on Friday, hitting $31.48. The stock had a trading volume of 326,504 shares, compared to its average volume of 676,789. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market cap of $1.75 billion, a P/E ratio of -12.49 and a beta of 2.16. The business has a fifty day moving average price of $27.44 and a two-hundred day moving average price of $32.04. Maze Therapeutics, Inc. has a 1-year low of $21.95 and a 1-year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). On average, sell-side analysts predict that Maze Therapeutics, Inc. will post -2.70 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Sterling Capital Management LLC lifted its position in Maze Therapeutics by 390.5% in the 3rd quarter. Sterling Capital Management LLC now owns 1,089 shares of the company’s stock worth $30,000 after buying an additional 867 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Maze Therapeutics during the second quarter worth approximately $48,000. Royal Bank of Canada lifted its holdings in shares of Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after acquiring an additional 1,383 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Maze Therapeutics in the 2nd quarter worth approximately $80,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Maze Therapeutics in the 3rd quarter valued at $77,000.

Analysts Set New Price Targets

Several research analysts have weighed in on MAZE shares. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush reaffirmed an “outperform” rating and set a $48.00 target price on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. Finally, HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. Three analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $64.45.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.